ReviewMicrobial biotechnology2023
Novel antimicrobial strategies to treat multi-drug resistant Staphylococcus aureus infections.
Review in Microbial biotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Antimicrobial resistance in wild game mammals: a glimpse into the contamination of wild habitats in a systematic review and meta-analysis.BMC veterinary research · 2025Pooled it
- Experimental evolution of phage K enhances antibacterial activity against USA300 MRSA in lung infection models.Emerging microbes & infections · 2026Article
- Mocravimod as a repurposing drug against clinical isolates ofMicrobiology spectrum · 2026Article
- Unveiling the antibacterial activity and mechanisms of BMS-303141 against Staphylococcus aureus.BMC microbiology · 2026Article
- Anti-Inflammatory Effects of Pingyin Rose Essential Oil in LPS-Induced HaCaT Cells: An in Vitro and in Silico Study.International journal of molecular sciences · 2026Article
- Antimicrobial Peptides Against Antimicrobial-Resistant Bacteria: Focus on Machine Learning.Infection and drug resistance · 2026Review
- From Structure to Function: 2-Chloro-5-nitrobenzoic Acid Derivatives as Potential Next-Generation Antibacterials.International journal of molecular sciences · 2025Article
- Preclinical evaluation of repositioned non-antibiotic agents against Staphylococcus aureus: a network meta-analysis of survival outcomes.World journal of microbiology & biotechnology · 2025Article
- Activity of lactic acid bacteria against biofilms formed by Staphylococcus aureus strains involved in acute mastitis.Scientific reports · 2025Article
- Synthesis of Urea-Containing Derivatives and their Application as Potential Anti-Methicillin-Resistant Staphylococcus Aureus Agents.ChemMedChem · 2025Article
- Article
- Repurposing AZD-5991 for inhibiting growth and biofilm formation of Staphylococcus aureus by disrupting the cell membrane and targeting FabI.BMC microbiology · 2025Article
- Exploring the Potential of Phytocannabinoids Against Multidrug-Resistant Bacteria.Plants (Basel, Switzerland) · 2025Article
- Review
- Anti-staphylococcal fatty acids: mode of action, bacterial resistance and implications for therapeutic application.Microbiology (Reading, England) · 2025Review
- In Vitro and In Vivo Investigations into the Potential of Quinazoline and Quinoline Derivatives as NorA Efflux Pump Inhibitors Against ResistantAntibiotics (Basel, Switzerland) · 2025Article
- In Silico Approach for Antibacterial Discovery: PTML Modeling of Virtual Multi-Strain Inhibitors AgainstPharmaceuticals (Basel, Switzerland) · 2025Article
- The Secondary Resistome of Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- Antibiotic Resistance ofPharmaceuticals (Basel, Switzerland) · 2025Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial resistance is a major obstacle for the treatment of infectious diseases and currently represents one of the most significant threats to global health. Staphylococcus aureus remains a formidable human pathogen with high mortality rates associated with severe systemic infections. S. aureus has become notorious as a multidrug resistant bacterium, which when combined with its extensive arsenal of virulence factors that exacerbate disease, culminates in an incredibly challenging pathogen to treat clinically. Compounding this major health issue is the lack of antibiotic discovery and development, with only two new classes of antibiotics approved for clinical use in the last 20 years. Combined efforts from the scientific community have reacted to the threat of dwindling treatment options to combat S. aureus disease in several innovative and exciting developments. This review describes current and future antimicrobial strategies aimed at treating staphylococcal colonization and/or disease, examining therapies that show significant promise at the preclinical development stage to approaches that are currently being investigated in clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.